Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 11/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 10/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 3/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19575386 | 0.80 | LMNA (0.57) | PRMT5WDR77POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL14633229 | 0.78 | PDPK1 (0.46) | PRMT5WDR77POLBARTSHR | |
| SCHEMBL10223032 | 0.76 | GRM4 (0.37) | — | |
| SCHEMBL18237606 | 0.74 | POLB (0.41) | PRMT5WDR77POLBSMN1; SMN2TSHR | |
| SCHEMBL30169667 | 0.74 | PARP1 (0.62) | PRMT5WDR77POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL24835102 | 0.74 | PARP1 (0.62) | PRMT5WDR77POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL4925641 | 0.73 | ALDH1A1 (0.36) | PRMT5WDR77ALDH1A1LMNA | |
| SCHEMBL19902654 | 0.72 | PRMT5 (0.44) | PRMT5WDR77POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL19153918 | 0.71 | PDPK1 (0.42) | PRMT5WDR77ALDH1A1PARP1 | |
| SCHEMBL19131364 | 0.71 | POLB (0.35) | POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051327-B2 | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases | ABBVIE INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140296220-A1 | PYRIDAZINO[4,5-D]PYRIMIDIN-5(6H)-ONE INHIBITORS OF KINASES | ABBVIE INC (US) | 2014-10-02 | — | — | US | disclosed |
| US-8796289-B2 | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases | ABBVIE INC. (US) | 2014-08-05 | — | — | US | disclosed |
| WO-2013013031-A1 | PYRIDAZINO [4, 5 -D] PYRIMIDIN- (6H) -ONE INHIBITORS OF WEE - 1 KINASE | ABBVIE INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20130023523-A1 | PYRIDAZINO[4,5-D]PYRIMIDIN-5(6H)-ONE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296220-A1 | PYRIDAZINO[4,5-D]PYRIMIDIN-5(6H)-ONE INHIBITORS OF KINASES | WEE1, WEE2, CDK1 | PRMT5 546/4885WDR77 1052/4885POLB 1396/4885 |
| US-20130023523-A1 | PYRIDAZINO[4,5-D]PYRIMIDIN-5(6H)-ONE INHIBITORS OF KINASES | WEE1, WEE2, CDK1 | PRMT5 546/4885WDR77 1052/4885POLB 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.